Get the Stockscreener App
28.42
4.41%
-1.31
Arcus Biosciences Inc stock is traded at $28.42, with a volume of 1.23M.
It is down -4.41% in the last 24 hours and down -1.32% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$29.73
Open:
$30.02
24h Volume:
1.23M
Relative Volume:
0.94
Market Cap:
$3.57B
Revenue:
$236.00M
Net Income/Loss:
$-369.00M
P/E Ratio:
-8.9292
EPS:
-3.1828
Net Cash Flow:
$-489.00M
1W Performance:
+3.84%
1M Performance:
-1.32%
6M Performance:
+28.42%
1Y Performance:
+187.94%
1-Day Range:
$28.33
$30.17
1-Week Range:
$28.01
$31.09
52-Week Range:
$8.84
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
28.42 | 3.57B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Price to sales forward of Arcus Biosciences, Inc. – NYSE:RCUS - TradingView
RCUS|Arcus Biosciences Inc|Price:28.430|Chg%:-1.300 - TradingKey
Arcus: 'Buy' Casdatifan Late-Stage ccRCC Advancement And 1st-Line Expansions (NYSE:RCUS) - Seeking Alpha
H.C. Wainwright reiterates Arcus Biosciences stock rating at buy By Investing.com - Investing.com Canada
Why Did Arcus Biosciences (NYSE:RCUS) Announce New Trial? - Kalkine Media
Arcus Biosciences (RCUS) Partners with Summit Therapeutics for K - GuruFocus
Arcus Biosciences (RCUS) Forms Clinical Supply Agreement with AV - GuruFocus
Arcus Biosciences And Summit Therapeutics Enter Into Clinical Trial Collaboration - TradingView
A planned study will compare treatments in advanced kidney cancer - Stock Titan
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - Business Wire
Arcus Biosciences to host Q2 2026 financial results call - scanx.trade
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Arcus Biosciences to Discuss Cancer and Autoimmune Pipeline Aug. 5 - Stock Titan
(RCUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%? - Benzinga
Arcus Biosciences Jumps 5.5% After HC Wainwright & Co. Maintains Buy - AlphaStreet
RCUS Maintained by HC Wainwright & Co. -- Price Target Raised to $45 - GuruFocus
H.C. Wainwright raises Arcus Biosciences stock price target to $45 By Investing.com - Investing.com Canada
This Insider Has Just Sold Shares In Arcus Biosciences - simplywall.st
Arcus Biosciences President Sells 68,569 Shares in July 2026 - sekbernews.id
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run - The Motley Fool
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run - The Motley Fool
Arcus Biosciences (RCUS) president trades 68,569 shares under 10b5-1 plan - Stock Titan
Arcus Biosciences president Juan C. Jaen sells $2.03m in shares - Investing.com Canada
Form 4 Arcus Biosciences Inc For: 13 July By Investing.com - Investing.com UK
Form 144 Arcus Biosciences For: 9 July By Investing.com - Investing.com Nigeria
Trust files proposed RCUS Class A sales (RCUS) — multiple dates and amounts - Stock Titan
Arcus Biosciences awards stock options to five new employees - Stock Titan
Arcus Biosciences grants options and RSUs to new employees - scanx.trade
Arcus Biosciences (RCUS) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer - AOL.com
Arcus Biosciences Announces New Employment Inducement Grants - AOL.com
Arcus Biosciences (RCUS) Surges 4.88% as Shares Test Key Resistance LevelThematic ETF Flow - dars.gov.et
Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus - Sahm
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data - Sahm
Arcus Biosciences (RCUS) Surges 4.88%: Momentum Builds Near ResistanceFactor ETF Flow - dars.gov.et
Arcus Biosciences stock extends recent pullback as technical signals favor stabilization - Traders Union
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Yahoo Finance
RCUSArcus Biosciences Inc Latest SEC Filings - Finviz
Arcus Biosciences stock drops 2.43% as Nature publication highlights kidney cancer research, arcusbio says - Traders Union
Arcus kidney cancer drug shows 12.2-month median survival By Investing.com - Investing.com Nigeria
HIF-2a inhibition with casdatifan (IMAGE) - EurekAlert!
Arcus Biosciences (RCUS) Unveils Promising ARC-20 Study Findings on Casdatifan - GuruFocus
Arcus kidney cancer drug shows 12.2-month median survival - Investing.com
New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan - EurekAlert!
Arcus study links EPO suppression to kidney cancer survival - scanx.trade
ETFs Investing in Arcus Biosciences, Inc. Stocks - TradingView
Arcus Biosciences (RCUS) Holds Steady Near Support as Biotech Sector Shows Mixed SignalsDark Pool Prints - dars.gov.et
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcus Biosciences Inc (RCUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arcus Biosciences, Inc. (RCUS) reports Q1 loss, beats revenue estimates - MSN
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):